Q3 2024 EPS Estimates for Danaher Co. Reduced by William Blair (NYSE:DHR)

Danaher Co. (NYSE:DHR) – Stock analysts at William Blair cut their Q3 2024 EPS estimates for shares of Danaher in a research note issued to investors on Tuesday, July 23rd. William Blair analyst M. Larew now forecasts that the conglomerate will post earnings per share of $1.56 for the quarter, down from their prior forecast of $1.73. The consensus estimate for Danaher’s current full-year earnings is $7.60 per share. William Blair also issued estimates for Danaher’s Q3 2025 earnings at $1.87 EPS and Q4 2025 earnings at $2.82 EPS.

DHR has been the topic of a number of other research reports. Citigroup raised their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and raised their price objective for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Robert W. Baird raised their price objective on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a report on Wednesday. Stifel Nicolaus raised their price objective on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday. Finally, Bank of America raised their price objective on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday. Six investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $276.88.

Danaher Stock Performance

Shares of NYSE DHR opened at $274.13 on Thursday. The company has a quick ratio of 1.51, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The company has a market cap of $197.98 billion, a PE ratio of 46.46, a PEG ratio of 4.11 and a beta of 0.83. The firm’s 50-day moving average price is $255.16 and its 200-day moving average price is $249.09. Danaher has a 52-week low of $182.09 and a 52-week high of $277.72.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter last year, the firm posted $2.05 EPS.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 26th. Stockholders of record on Friday, June 28th were given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. The ex-dividend date of this dividend was Friday, June 28th. Danaher’s payout ratio is currently 18.31%.

Insider Activity

In other news, CFO Matthew Mcgrew sold 46,377 shares of Danaher stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the sale, the chief financial officer now owns 29,407 shares in the company, valued at $7,441,441.35. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the sale, the director now owns 116,202 shares in the company, valued at $28,304,483.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Matthew Mcgrew sold 46,377 shares of the business’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the completion of the sale, the chief financial officer now owns 29,407 shares in the company, valued at approximately $7,441,441.35. The disclosure for this sale can be found here. Insiders have sold a total of 84,775 shares of company stock worth $21,802,690 over the last quarter. Insiders own 11.10% of the company’s stock.

Institutional Investors Weigh In On Danaher

Several large investors have recently bought and sold shares of DHR. Patrick M Sweeney & Associates Inc. boosted its stake in Danaher by 3.4% during the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after buying an additional 40 shares during the period. Trust Co of Kansas boosted its stake in Danaher by 4.1% during the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock worth $255,000 after buying an additional 40 shares during the period. ST Germain D J Co. Inc. boosted its stake in Danaher by 1.4% during the first quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock worth $719,000 after buying an additional 41 shares during the period. Godsey & Gibb Inc. boosted its stake in Danaher by 3.0% during the first quarter. Godsey & Gibb Inc. now owns 1,442 shares of the conglomerate’s stock worth $360,000 after buying an additional 42 shares during the period. Finally, Premier Path Wealth Partners LLC boosted its stake in Danaher by 1.8% during the second quarter. Premier Path Wealth Partners LLC now owns 2,345 shares of the conglomerate’s stock worth $586,000 after buying an additional 42 shares during the period. Institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.